265 related articles for article (PubMed ID: 27903973)
1. Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.
Yan H; Wen L; Tan D; Xie P; Pang FM; Zhou HH; Zhang W; Liu ZQ; Tang J; Li X; Chen XP
Oncotarget; 2017 Jan; 8(1):1529-1540. PubMed ID: 27903973
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia.
He X; Zhang W; Fu W; Liu X; Yang P; Wang J; Zhu M; Li S; Zhang W; Zhang X; Dong G; Yan C; Zhao Y; Zeng Z; Jing H
Cancer Biomark; 2023; 36(2):103-116. PubMed ID: 36404533
[TBL] [Abstract][Full Text] [Related]
3. A novel 5-gene prognostic signature to improve risk stratification of cytogenetically normal acute myeloid leukemia.
Deng C; Zeng T; Zhu P; Zhao S; Huang Z; Huang W; Zhang W; Huang X; Fu L
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10015-10025. PubMed ID: 37258721
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
5. TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients.
Liu H; Chen P; Yang YL; Zhu KW; Wang T; Tang L; Liu YL; Cao S; Zhou G; Zeng H; Zhao XL; Zhang W; Chen XP
Eur J Pharmacol; 2021 Mar; 895():173894. PubMed ID: 33476656
[TBL] [Abstract][Full Text] [Related]
6. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of GMI signature based random survival forest prognosis model to predict clinical outcome in acute myeloid leukemia.
Shi M; Xu G
BMC Med Genomics; 2019 Jun; 12(1):90. PubMed ID: 31242922
[TBL] [Abstract][Full Text] [Related]
9. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
[TBL] [Abstract][Full Text] [Related]
10. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
Metzeler KH; Hummel M; Bloomfield CD; Spiekermann K; Braess J; Sauerland MC; Heinecke A; Radmacher M; Marcucci G; Whitman SP; Maharry K; Paschka P; Larson RA; Berdel WE; Büchner T; Wörmann B; Mansmann U; Hiddemann W; Bohlander SK; Buske C; ;
Blood; 2008 Nov; 112(10):4193-201. PubMed ID: 18716133
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
Lamba JK; Pounds S; Cao X; Crews KR; Cogle CR; Bhise N; Raimondi SC; Downing JR; Baker SD; Ribeiro RC; Rubnitz JE
Leuk Lymphoma; 2016; 57(4):909-20. PubMed ID: 26366682
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
Zhou S; Liu P; Zhang H
Mol Med Rep; 2017 Jul; 16(1):281-287. PubMed ID: 28498449
[TBL] [Abstract][Full Text] [Related]
13. Higher Expression of
Chen C; Chen Z; Chio CL; Zhao Y; Li Y; Liu Z; Jin Z; Wu X; Wei W; Zhao Q; Li Y
Technol Cancer Res Treat; 2021; 20():15330338211052152. PubMed ID: 34738847
[No Abstract] [Full Text] [Related]
14. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
15. An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype.
Chuang MK; Chiu YC; Chou WC; Hou HA; Tseng MH; Kuo YY; Chen Y; Chuang EY; Tien HF
Oncotarget; 2015 Nov; 6(36):39098-110. PubMed ID: 26517675
[TBL] [Abstract][Full Text] [Related]
16. A 4-microRNA signature for survival prognosis in pediatric and adolescent acute myeloid leukemia.
Zhu R; Lin W; Zhao W; Fan F; Tang L; Hu Y
J Cell Biochem; 2019 Mar; 120(3):3958-3968. PubMed ID: 30242879
[TBL] [Abstract][Full Text] [Related]
17. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
Lamba JK; Crews KR; Pounds SB; Cao X; Gandhi V; Plunkett W; Razzouk BI; Lamba V; Baker SD; Raimondi SC; Campana D; Pui CH; Downing JR; Rubnitz JE; Ribeiro RC
Pharmacogenomics; 2011 Mar; 12(3):327-39. PubMed ID: 21449673
[TBL] [Abstract][Full Text] [Related]
18. SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.
Kim JH; Lee C; Cheong HS; Koh Y; Ahn KS; Kim HL; Shin HD; Yoon SS
Cancer Chemother Pharmacol; 2016 Sep; 78(3):533-40. PubMed ID: 27422302
[TBL] [Abstract][Full Text] [Related]
19. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.
Marcucci G; Yan P; Maharry K; Frankhouser D; Nicolet D; Metzeler KH; Kohlschmidt J; Mrózek K; Wu YZ; Bucci D; Curfman JP; Whitman SP; Eisfeld AK; Mendler JH; Schwind S; Becker H; Bär C; Carroll AJ; Baer MR; Wetzler M; Carter TH; Powell BL; Kolitz JE; Byrd JC; Plass C; Garzon R; Caligiuri MA; Stone RM; Volinia S; Bundschuh R; Bloomfield CD
J Clin Oncol; 2014 Feb; 32(6):548-56. PubMed ID: 24378410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
